On Wednesday, Amazon.com, Inc. (NASDAQ:AMZN)’s shares inclined 0.13% to $427.81.
Amazon.com, Inc. (AMZN) introduced the all-new Kindle Paperwhite, updating its most popular and best-selling Kindle with the highest resolution Paperwhite display, the exclusive Kindle font Bookerly, and a new typesetting engine for more beautiful pages. Meet the new Kindle Paperwhite at www.amazon.com/paperwhite.
New, Highest Resolution Paperwhite Display—300 Pixels per Inch for Laser-Quality Text
The new Kindle Paperwhite adds our highest resolution Paperwhite display, delivering the same 300 pixels per inch that readers love about the top-of-the-line Kindle Voyage. With unsurpassed resolution and 2x the pixels as the previous generation Kindle Paperwhite, the display delivers laser-quality text, making it easy to read comfortably at any font size, counting at smaller fonts so you can fit more words on each page. Even with the new higher resolution display, Kindle Paperwhite delivers battery life that is measured in weeks rather than hours.
New Bookerly Font and Typography Features—Read Faster With Less Eyestrain
Kindle Paperwhite now offers Bookerly, an exclusive font designed from the ground up for reading on digital screens. Warm and contemporary, Bookerly is inspired by the artistry of the best fonts in modern print books, but is hand-crafted for great readability at any size. It introduces a lighter, more graceful look and outperforms other digital reading fonts to assist customers read faster with less eyestrain. See Bookerly: www.amazon.com/bookerly.
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates in two segments, North America and International. The company serves consumers through retail Websites, such as amazon.com and amazon.ca, which primarily comprise merchandise and content purchased for resale from vendors and those offered by third-party sellers.
Hill-Rom Holdings, Inc. (NYSE:HRC)’s shares gained 6.34% to $55.70.
Two of the world’s leading healthcare technology companies are joining forces to make possible the development of leading-edge solutions that will advance patient care around the world. Hill-Rom Holdings, Inc. (HRC) (“Hill-Rom”) and privately-held Welch Allyn, Inc. (“Welch Allyn”) recently declared that the Boards of Directors of both companies have unanimously approved a definitive agreement under which Hill-Rom will acquire Welch Allyn for about $2.05 billion in cash and stock. The two companies have nearly two centuries of medical device innovation between them and will combine their unique strengths to develop new technologies that enhance outcomes for patients and their caregivers.
Under the terms of the agreement, Welch Allyn shareholders will receive $1.625 billion in cash and about 8.1 million newly-issued shares of Hill-Rom common stock.
Upon the completion of the transaction, which the companies expect will occur before the end of September 2015, Welch Allyn shareholders, a group that comprises of about 75 shareholders, will own about 13 percent of the combined company. No single Welch Allyn shareholder will own more than about one percent of Hill-Rom equity.
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. The company operates through three segments: North America, Surgical and Respiratory Care, and International. It provides patient care systems, counting various bed systems, in addition to mobility solutions; and patient/resident room solutions, which comprise architectural products and health care furniture.
At the end of Wednesday’s trade, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘s shares surged 0.23% to $4.38.
Arena Pharmaceuticals, Inc. (ARNA) declared that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue another opportunity in the biotechnology industry. Mr. Hoffman is predictable to remain in his current role at Arena until July 10, 2015.
Following Mr. Hoffman’s departure, Jennifer K. Bielasz, Arena’s Vice President, Accounting and Controller, will continue to play a key leadership role in Arena’s finance department. Ms. Bielasz joined Arena in 2001 and is responsible for managing all accounting activities. Prior to joining Arena, Ms. Bielasz served as the controller of both public and private companies and began her career at KPMG LLP.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases.
MBIA Inc. (NYSE:MBI), ended its Wednesday’s trading session with -3.22% loss, and closed at $8.72.
National Public Finance Guarantee Corporation (National), an indirect partner of MBIA Inc. (MBI), declared that Thomas M. Metzold will join the company as Managing Director and Head of Capital Markets in early August. In this newly created position, Mr. Metzold will be responsible for leading National’s secondary markets business and for coordinating the firm’s outreach to buy and sell-side municipal bond trading desks. Mr. Metzold joins National following a 28-year career at Eaton Vance Administration, where he was a Senior Municipal Portfolio Advisor and portfolio manager for about $5.5 billion of municipal assets.
MBIA Inc. provides financial guarantee insurance services to public finance markets in the United States and internationally. The company operates through U.S. Public Finance Insurance, and International and Structured Finance Insurance segments. It issues financial guarantees for municipal bonds, counting tax-exempt and taxable indebtedness, in addition to utility districts, airports, health care institutions, higher educational facilities, student loan issuers, housing authorities, and other similar agencies and obligations issued by private entities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
